Complications Associated with Worse Visual Outcomes in Patients with Exudative Neovascular Age-Related Macular Degeneration

https://doi.org/10.1016/S2214-109X(13)70145-1

2.

Wong

WL

,

Su

X

,

Li

X

,

Cheung

CM

,

Klein

R

,

Cheng

CY

,

Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis

.

Lancet Glob Health

.

2014

;

2

(

2

):

e106

–

16

.

.

https://doi.org/10.1016/j.ophtha.2019.11.004

3.

Spaide

RF

,

Jaffe

GJ

,

Sarraf

D

,

Freund

KB

,

Sadda

SR

,

Staurenghi

G

,

Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group

.

Ophthalmology

.

2020

;

127

(

5

):

616

–

36

.

.

https://doi.org/10.1016/j.ophtha.2012.10.036

4.

Ferris

FL

,

Wilkinson

CP

,

Bird

A

,

Chakravarthy

U

,

Chew

E

,

Csaky

K

,

Clinical classification of age-related macular degeneration

.

Ophthalmology

.

2013 Apr

;

120

(

4

):

844

–

51

.

.

https://doi.org/10.1002/14651858.CD005139.pub4

5.

Solomon

SD

,

Lindsley

K

,

Vedula

SS

,

Krzystolik

MG

,

Hawkins

BS

.

Anti-vascular endothelial growth factor for neovascular age-related macular degeneration

.

Cochrane Database Syst Rev

.

2019

;

3

(

3

):

CD005139

.

.

https://doi.org/10.1136/bmj.c2459

6.

Tufail

A

,

Patel

PJ

,

Egan

C

,

Hykin

P

,

Da Cruz

L

,

Gregor

Z

,

Bevacizumab for neovascular age related macular degeneration (ABC trial): multicentre randomised double masked study

.

BMJ

.

2010

;

340

(

7761

):

c2459

.

.

https://doi.org/10.1038/eye.2008.423

7.

Sacu

S

,

Michels

S

,

Prager

F

,

Weigert

G

,

Dunavoelgyi

R

,

Geitzenauer

W

,

Randomised clinical trial of intravitreal avastin versus photodynamic therapy and intravitreal triamcinolone: long-term results

.

Eye

.

2009

;

23

(

12

):

2223

–

7

.

.

https://doi.org/10.1016/j.ajo.2007.10.004

8.

Regillo

CD

,

Brown

DM

,

Abraham

P

,

Yue

H

,

Ianchulev

T

,

Schneider

S

,

Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1

.

Am J Ophthalmol

.

2008

;

145

(

2

):

239

.

.

9.

Maberley

D

.

Pegaptanib for neovascular age-related macular degeneration

.

Issues Emerg Health Technol

.

2005

;

76

:

1

–

4

..

https://doi.org/10.1056/NEJMoa062655

10.

Brown

DM

,

Kaiser

PK

,

Michels

M

,

Soubrane

G

,

Heier

JS

,

Kim

RY

,

Ranibizumab versus verteporfin for neovascular age-related macular degeneration

.

N Engl J Med

.

2006

;

355

(

14

):

1432

–

44

.

.

11.

Seddon

JM

,

McLeod

DS

,

Bhutto

IA

,

Villalonga

MB

,

Silver

RE

,

Wenick

AS

,

Histopathological insights into choroidal vascular loss in clinically documented cases of age-related macular degeneration

.

JAMA Ophthalmol

.

2016 Sep

.

https://doi.org/10.1016/j.exer.2005.04.012

12.

Curcio

CA

,

Presley

JB

,

Malek

G

,

Medeiros

NE

,

Avery

DV

,

Kruth

HS

.

Esterified and unesterified cholesterol in drusen and basal deposits of eyes with age-related maculopathy

.

Exp Eye Res

.

2005 Dec

;

81

(

6

):

731

–

41

.

.

https://doi.org/10.1167/iovs.09-3639

13.

McLeod

DS

,

Grebe

R

,

Bhutto

I

,

Merges

C

,

Baba

T

,

Lutty

GA

.

Relationship between RPE and choriocapillaris in age-related macular degeneration

.

Invest Ophthalmol Vis Sci

.

2009 Oct

;

50

(

10

):

4982

–

91

.

.

https://doi.org/10.1016/0039-6257(88)90052-5

14.

Bressler

NM

,

Bressler

SB

,

Fine

SL

.

Age-related macular degeneration

.

Surv Ophthalmol

.

1988

;

32

(

6

):

375

–

413

.

.

15.

Fine

AM

,

Elman

MJ

,

Ebert

JE

,

Prestia

PA

,

Starr

JS

,

Fine

SL

.

Earliest symptoms caused by neovascular membranes in the macula

.

Arch Ophthalmol

.

1986

;

104

(

4

):

513

.

16.

Bressler

NM

,

Chang

TS

,

Suñer

IJ

,

Fine

JT

,

Dolan

CM

,

Ward

J

,

Vision-related function after ranibizumab treatment by better- or worse-seeing eye. clinical trial results from marina and anchor

.

Ophthalmology

.

2010

;

117

(

4

):

747

.

https://doi.org/10.1016/s0161-6420(82)34840-x

17.

Yannuzzi

LA

.

A modified Amsler grid. A self-assessment test for patients with macular disease

.

Ophthalmology

.

1982 Feb

;

89

(

2

):

157

–

9

.

.

18.

Martin

DF

,

Maguire

MG

,

Fine

SL

,

Ying

GS

,

Jaffe

GJ

,

Grunwald

JE

,

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results

.

Ophthalmology

.

2012

;

119

(

7

):

1388

.

https://doi.org/10.1016/j.ophtha.2012.10.014

19.

Busbee

BG

,

Ho

AC

,

Brown

DM

,

Heier

JS

,

Suñer

IJ

,

Li

Z

,

Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration

.

Ophthalmology

.

2013

;

120

(

5

):

1046

–

56

.

.

20.

Chakravarthy

U

,

Harding

SP

,

Rogers

CA

,

Downes

SM

,

Lotery

AJ

,

Culliford

LA

,

Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial

.

Lancet

.

2013

;

382

(

9900

):

1258

.

21.

Gupta

OP

,

Shienbaum

G

,

Patel

AH

,

Fecarotta

C

,

Kaiser

RS

,

Regillo

CD

.

A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration: clinical and economic impact

.

Ophthalmology

.

2010

;

117

(

11

):

2134

.

22.

Shienbaum

G

,

Gupta

OP

,

Fecarotta

C

,

Patel

AH

,

Kaiser

RS

,

Regillo

CD

.

Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact

.

Am J Ophthalmol

.

2012

;

153

(

3

):

468

.

23.

Silva

R

,

Berta

A

,

Larsen

M

,

Macfadden

W

,

Feller

C

,

Monés

J

.

Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the trend study

.

Ophthalmology

.

2018

;

125

(

1

):

57

.

24.

Berg

K

,

Hadzalic

E

,

Gjertsen

I

,

Forsaa

V

,

Berger

LH

,

Kinge

B

,

Ranibizumab or bevacizumab for neovascular age-related macular degeneration according to the lucentis compared to avastin study treat-and-extend protocol: two-year results

.

Ophthalmology

.

2016

;

123

(

1

):

51

.

25.

Wykoff

CC

,

Croft

DE

,

Brown

DM

,

Wang

R

,

Payne

JF

,

Clark

L

,

Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results

.

Ophthalmology

.

2015;122(12):2514–22

.

https://doi.org/10.1016/j.oret.2016.12.004

26.

Wykoff

CC

,

Ou

WC

,

Brown

DM

,

Croft

DE

,

Wang

R

,

Payne

JF

,

Randomized trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: 2-year results of the TREX-AMD study

.

Ophthalmol Retina

.

2017 Jul

;

1

(

4

):

314

–

21

.

.

https://doi.org/10.1016/j.survophthal.2015.04.004

27.

Stanescu-Segall

D

,

Balta

F

,

Jackson

TL

.

Submacular hemorrhage in neovascular age-related macular degeneration: a synthesis of the literature

.

Surv Ophthalmol

.

2016

;

61

(

1

):

18

–

32

.

.

28.

El Baba

F

,

Jarrett

WH

,

Harbin

TS

,

Fine

SL

,

Michels

RG

,

Schachat

AP

,

Massive hemorrhage complicating age-related macular degeneration: clinicopathologic correlation and role of anticoagulants

.

Ophthalmology

.

1986

;

93

(

12

):

1581

–

92

.

29.

Ying

GS

,

Maguire

MG

,

Daniel

E

,

Grunwald

JE

,

Ahmed

O

,

Martin

DF

.

Association between antiplatelet or anticoagulant drugs and retinal or subretinal hemorrhage in the comparison of age-related macular degeneration treatments trials

.

Ophthalmology

.

2016

;

123

(

2

):

352

.

30.

Argon laser photocoagulation for neovascular maculopathy: five-year results from randomized clinical trials

.

Arch Ophthalmol

.

1991

;

109

(

8

):

1109

.

31.

Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration: updated findings from two clinical trials

.

Arch Ophthalmol

.

1993

;

111

(

9

):

1200

.

32.

Hawkins BS

.

Laser photocoagulation of subfoveal recurrent neovascular lesions in age-related macular degeneration: results of a randomized clinical trial

.

Arch Ophthalmol

.

1991

;

109

(

9

):

1232

.

https://doi.org/10.1097/00006982-199616030-00001

33.

Avery

RL

,

Fekrat

S

,

Hawkins

BS

,

Bressler

NM

.

Natural history of subfoveal subretinal hemorrhage in age-related macular degeneration

.

Retina

.

1996

;

16

(

3

):

183

–

9

.

.

https://doi.org/10.1001/archopht.1991.01080050139046

34.

Toth

CA

,

Morse

LS

,

Hjelmeland

LM

,

Landers

MB

.

Fibrin directs early retinal damage after experimental subretinal hemorrhage

.

Arch Ophthalmol

.

1991

;

109

(

5

):

723

–

9

.

.

https://doi.org/10.1016/s0002-9394(14)75575-8

35.

Bennett

SR

,

Folk

JC

,

Blodi

CF

,

Klugman

M

.

Factors prognostic of visual outcome in patients with subretinal hemorrhage

.

Am J Ophthalmol

.

1990 Jan

;

109

(

1

):

33

–

7

.

.

https://doi.org/10.1159/000360469

36.

Yiu

G

,

Mahmoud

TH

.

Subretinal hemorrhage

.

Dev Ophthalmol

.

2014

;

54

:

213

–

22

.

.

https://doi.org/10.1038/eye.2008.267

37.

Sacu

S

,

Stifter

E

,

Vécsei-Marlovits

PV

,

Michels

S

,

Schütze

C

,

Prünte

C

,

Management of extensive subfoveal haemorrhage secondary to neovascular age-related macular degeneration

.

Eye

.

2009

;

23

(

6

):

1404

–

10

.

.

https://doi.org/10.1016/S0161-6420(99)90399-8

38.

Hassan

AS

,

Johnson

MW

,

Schneiderman

TE

,

Regillo

CD

,

Tornambe

PE

,

Poliner

LS

,

Management of submacular hemorrhage with intravitreous tissue plasminogen activator injection and pneumatic displacement

.

Ophthalmology

.

1999

;

106

(

10

):

1900

–

7

.

.

https://doi.org/10.1097/01.iae.0000237586.48231.75

39.

Chen

CY

,

Hooper

C

,

Chiu

D

,

Chamberlain

M

,

Karia

N

,

Heriot

WJ

.

Management of submacular hemorrhage with intravitreal injection of tissue plasminogen activator and expansile gas

.

Retina

.

2007

;

27

(

3

):

321

–

8

.

.

https://doi.org/10.1136/bjophthalmol-2011-300655

40.

Treumer

F

,

Roider

J

,

Hillenkamp

J

.

Long-term outcome of subretinal coapplication of rtPA and bevacizumab followed by repeated intravitreal anti-VEGF injections for neovascular AMD with submacular haemorrhage

.

Br J Ophthalmol

.

2012

;

96

(

5

):

708

–

13

.

.

https://doi.org/10.1136/bjo.2009.164707

41.

Treumer

F

,

Klatt

C

,

Roider

J

,

Hillenkamp

J

.

Subretinal coapplication of recombinant tissue plasminogen activator and bevacizumab for neovascular age-related macular degeneration with submacular haemorrhage

.

Br J Ophthalmol

.

2010

;

94

(

1

):

48

–

53

.

.

https://doi.org/10.3341/kjo.2020.0014

42.

Kim

TY

,

Kang

HG

,

Choi

EY

,

Koh

HJ

,

Kim

SS

,

Lee

JH

,

Prognostic factors and long-term surgical outcomes for exudative age-related macular degeneration with breakthrough vitreous hemorrhage

.

Korean J Ophthalmol

.

2020

;

34

(

4

):

281

–

9

.

.

https://doi.org/10.1177/112067219100100307

43.

Azzolini

C

,

Menchini

U

,

Pece

A

,

Camesasca

F

,

Giuliani

V

.

Age-related macular degeneration and vitreous hemorrhage

.

Eur J Ophthalmol

.

1991

;

1

(

3

):

142

–

7

.

.

https://doi.org/10.1016/j.ajo.2009.09.012

44.

Hasegawa

T

,

Otani

A

,

Sasahara

M

,

Gotoh

N

,

Ooto

S

,

Tamura

H

,

Prognostic factors of vitreous hemorrhage secondary to exudative age-related macular degeneration

.

Am J Ophthalmol

.

2010 Feb 1

;

149

(

2

):

322

–

e1

.

.

https://doi.org/10.1038/s41598-019-57297-8

45.

Kim

JH

,

Kim

JW

,

Kim

CG

,

Lee

DW

.

Long-term clinical course after vitrectomy for breakthrough vitreous hemorrhage secondary to neovascular age-related macular degeneration and polypoidal choroidal vasculopathy

.

Sci Rep

.

2020

;

10

(

1

):

359

–

9

.

.

https://doi.org/10.1097/IAE.0b013e3181c969e9

46.

Jung

JH

,

Lee

JK

,

Lee

JE

,

Oum

BS

.

Results of vitrectomy for breakthrough vitreous hemorrhage associated with age-related macular degeneration and polypoidal choroidal vasculopathy

.

Retina

.

2010

;

30

(

6

):

865

–

73

.

.

47.

Roberts

SP

,

Roberts

DK

,

Stelmack

TR

.

Tears of the retinal pigment epithelium

.

Clin Eye Vis Care

.

1992

;

4

(

1

):

33

–

8

.

48.

Chang

LK

,

Sarraf

D

.

Tears of the retinal pigment epithelium: an old problem in a new era

.

Retina

.

2007

;

27

(

5

):

523

.

49.

Ersoz

MG

,

Karacorlu

M

,

Arf

S

,

Sayman Muslubas

I

,

Hocaoglu

M

.

Retinal pigment epithelium tears: classification, pathogenesis, predictors, and management

.

Surv Ophthalmol

.

2017

;

62

(

4

):

493

.

https://doi.org/10.1097/IAE.0000000000001062

50.

Mouallem

A

,

Sarraf

D

,

Chen

X

,

Capuano

V

,

Souied

EH

,

Querques

G

.

Double retinal pigment epithelium tears in neovascular age-related macular degeneration

.

Retina

.

2016 Nov

;

36

(

11

):

2197

–

204

.

.

https://doi.org/10.1016/j.jfo.2018.04.017

51.

Sastre-Ibáñez

M

,

Martínez-Rubio

C

,

Molina-Pallete

R

,

Martínez- López-Corell

P

,

Wu

L

,

Arévalo

JF

,

Retinal pigment epithelial tears

.

Journal Français d’Ophtalmologie

.

2019

;

42

(

1

):

63

–

72

.

.

https://doi.org/10.1159/000439445

52.

Clemens

CR

,

Eter

N

.

Retinal pigment epithelium tears: risk factors, mechanism and therapeutic monitoring

.

Ophthalmologica

.

2016

;

235

(

1

):

1

–

9

.

.

https://doi.org/10.1097/IAE.0000000000000056

53.

Doguizi

S

,

Ozdek

S

.

Pigment epithelial tears associated with anti-VEGF therapy: incidence, long-term visual outcome, and relationship with pigment epithelial detachment in age-related macular degeneration

.

Retina

.

2014

;

34

(

6

):

1156

–

62

.

.

54.

Sarraf

D

,

Chan

C

,

Rahimy

E

,

Abraham

P

.

Prospective evaluation of the incidence and risk factors for the development of RPE tears after high-and low-dose ranibizumab therapy

.

Retina

.

2013

;

33

(

8

):

1551

.

55.

Mukai

R

,

Sato

T

,

Kishi

S

.

Erratum: outsourced cataract surgery and postoperative endophthalmitis

.

Acta Ophthalmol

.

2014

;

92

(

5

):

2013

–

5

.

56.

Querques

G

,

Capuano

V

,

Costanzo

E

,

Corvi

F

,

Querques

L

,

Introini

U

,

Retinal pigment epithelium aperture: a previously unreported finding in the evolution of avascular pigment epithelium detachment

.

Retina

.

2016;36 Suppl 1:S65–S72

.

https://doi.org/10.1097/IAE.0b013e3181cdf366

57.

Sarraf

D

,

Reddy

S

,

Chiang

A

,

Yu

F

,

Jain

A

.

A new grading system for retinal pigment epithelial tears

.

Retina

.

2010

;

30

(

7

):

1039

–

45

.

.

https://doi.org/10.1097/IAE.0b013e318263d139

58.

Moreira

CA

,

Arana

LA

,

Zago

RJ

.

Long-term results of repeated anti-vascular endothelial growth factor therapy in eyes with retinal pigment epithelial tears

.

Retina

.

2013

;

33

(

2

):

277

–

81

.

.

59.

Sadda

SVR

,

Guymer

R

,

Monés

JM

,

Tufail

A

,

Jaffe

GJ

.

Anti–vascular endothelial growth factor use and atrophy in neovascular age-related macular degeneration: systematic literature review and expert opinion

.

Ophthalmology

.

2020

;

127

(

5

):

648

–

59

.

https://doi.org/10.1016/j.ophtha.2016.10.002

60.

Abdelfattah

NS

,

Al-Sheikh

M

,

Pitetta

S

,

Mousa

A

,

Sadda

SR

,

Wykoff

CC

,

Macular atrophy in neovascular age-related macular degeneration with monthly versus treat-and-extend ranibizumab: findings from the TREX-AMD trial

.

Ophthalmology

.

2017 Feb

;

124

(

2

):

215

–

23

.

.

https://doi.org/10.1016/j.ophtha.2017.12.026

61.

Sadda

SR

,

Tuomi

LL

,

Ding

B

,

Fung

AE

,

Hopkins

JJ

.

Macular atrophy in the harbor study for neovascular age-related macular degeneration

.

Ophthalmology

.

2018 Jun

;

125

(

6

):

878

–

86

.

.

62.

Grunwald

JE

,

Daniel

E

,

Huang

J

,

Ying

GS

,

Maguire

MG

,

Toth

CA

,

Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials

.

Ophthalmology

.

2014

;

121

(

1

):

150

.

https://doi.org/10.1136/bjophthalmol-2018-313685

63.

Querques

L

,

Parravano

M

,

Borrelli

E

,

Chiaravalloti

A

,

Tedeschi

M

,

Sacconi

R

,

Anatomical and functional changes in neovascular AMD in remission: comparison of fibrocellular and fibrovascular phenotypes

.

Br J Ophthalmol

.

2020

;

104

(

1

):

47

–

52

.

.

https://doi.org/10.1016/j.ajo.2018.05.008

64.

Abdelfattah

NS

,

Hariri

AH

,

Al-Sheikh

M

,

Pitetta

S

,

Ebraheem

A

,

Wykoff

CC

,

Topographic correspondence of macular atrophy with choroidal neovascularization in ranibizumab-treated eyes of the TREX-AMD trial

.

Am J Ophthalmol

.

2018 Aug

;

192

:

84

–

90

.

.

https://doi.org/10.1016/j.ophtha.2019.08.023

65.

Gillies

MC

,

Hunyor

AP

,

Arnold

JJ

,

Guymer

RH

,

Wolf

S

,

Pecheur

FL

,

Macular atrophy in neovascular age-related macular degeneration: a randomized clinical trial comparing ranibizumab and aflibercept (RIVAL study)

.

Ophthalmology

.

2020 Feb

;

127

(

2

):

198

–

210

.

.

66.

Guymer

RH

,

Markey

CM

,

McAllister

IL

,

Gillies

MC

,

Hunyor

AP

,

Arnold

JJ

,

Tolerating subretinal fluid in neovascular age-related macular degeneration treated with ranibizumab using a treat-and-extend regimen: fluid study 24-month results

.

Ophthalmology

.

2019

;

126

(

5

):

723

.

https://doi.org/10.2147/btt.s252581

67.

Akyol

E

,

Lotery

A

.

Gene, cell and antibody-based therapies for the treatment of age-related macular degeneration

.

Biologics

.

2020

;

14

:

83

–

94

.

.

https://doi.org/10.1109/MPULS.2019.2899702

68.

Mertz

L

.

Gift of sight: stem-cell patches for wet and dry macular degeneration

.

IEEE Pulse

.

2019

;

10

(

2

):

8

–

13

.

.

https://doi.org/10.3390/ijms20071693

69.

Nebbioso

M

,

Lambiase

A

,

Cerini

A

,

Limoli

PG

,

La Cava

M

,

Greco

A

.

Therapeutic approaches with intravitreal injections in geographic atrophy secondary to age-related macular degeneration: current drugs and potential molecules

.

Int J Mol Sci

.

2019

;

20

(

7

):

1693

.

.

https://doi.org/10.1016/j.oret.2019.09.017

70.

Kashani

AH

,

Uang

J

,

Mert

M

,

Rahhal

F

,

Chan

C

,

Avery

RL

,

Surgical method for implantation of a biosynthetic retinal pigment epithelium monolayer for geographic atrophy: experience from a phase 1/2a study

.

Ophthalmol Retina

.

2020

;

4

(

3

):

264

–

73

.

.

https://doi.org/10.1136/bjo.87.5.609

71.

Hogg

R

,

Curry

E

,

Muldrew

A

,

Winder

J

,

Stevenson

M

,

McClure

M

,

Identification of lesion components that influence visual function in age related macular degeneration

.

Br J Ophthalmol

.

2003

;

87

(

5

):

609

–

14

.

.

https://doi.org/10.1172/JCI31030

72.

Friedlander

M

.

Fibrosis and diseases of the eye

.

J Clin Invest

.

2007

;

117

:

576

–

86

.

.

https://doi.org/10.1016/j.preteyeres.2015.07.007

73.

Schmidt-Erfurth

U

,

Waldstein

SM

.

A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration

.

Prog Retin Eye Res

.

2016

;

50

:

1

–

24

.

.

https://doi.org/10.1001/archopht.116.6.745

74.

Grossniklaus

HE

,

Green

WR

.

Histopathologic and ultrastructural findings of surgically excised choroidal neovascularization. Submacular surgery trials research group

.

Arch Ophthalmol

.

1998

;

116

(

6

):

745

–

9

.

.

75.

Toth

CA

,

Tai

V

,

Pistilli

M

,

Chiu

SJ

,

Winter

K

,

Daniel

E

,

HHS Public Access

;

2020

.

https://doi.org/10.1016/j.oret.2017.08.019

76.

Casalino

G

,

Stevenson

MR

,

Bandello

F

,

Chakravarthy

U

.

Tomographic biomarkers predicting progression to fibrosis in treated neovascular age-related macular degeneration: a multimodal imaging study

.

Ophthalmol Retina

.

2018

;

2

(

5

):

451

–

61

.

.

77.

Daniel

E

,

Toth

CA

,

Grunwald

JE

,

Glenn

J

,

Martin

DF

,

Fine

SL

,

NIH public access

;

2015

.

https://doi.org/10.1001/archopht.116.2.203

78.

Hinton

DR

,

He

S

,

Lopez

PF

.

Apoptosis in surgically excised choroidal neovascular membranes in age-related macular degeneration

.

Arch Ophthalmol

.

1998

;

116

(

2

):

203

–

9

.

.

https://doi.org/10.1016/j.exer.2015.03.009

79.

Ishikawa

K

,

Kannan

R

,

Hinton

DR

.

Molecular mechanisms of subretinal fibrosis in age-related macular degeneration

.

Exp Eye Res

.

2014

;

142

:

19

–

25

.

.

https://doi.org/10.1097/APO.0000000000000291

80.

Samanta

A

,

Aziz

AA

,

Jhingan

M

,

Singh

SR

,

Khanani

A

,

Chhablani

J

.

Emerging therapies in neovascular age-related macular degeneration in 2020

.

Asia Pac J Ophthalmol

.

2020

;

9

(

3

):

250

–

9

.

.

https://doi.org/10.37765/ajmc.2020.43435

81.

Baumal

CR

.

Wet age-related macular degeneration: treatment advances to reduce the injection burden

.

Am J Manag Care

.

2020 May

;

26

(

5

):

S103

–

11

.

.

https://doi.org/10.1080/13543784.2021.1879791

82.

Nicolò

M

,

Ferro Desideri

L

,

Vagge

A

,

Traverso

CE

.

Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases

.

Expert Opin Investig Drugs

.

2021

;

30

(

3

):

193

–

200

.

.